Matinas Biopharma Holdings Inc.

Company Overview

Business Model: Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies utilizing its proprietary Lipid Nanocrystal (LNC) platform delivery technology. The Company's lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug. MAT2203 is positioned for a single Phase 3 registration trial (the ORALTO trial) for the treatment of invasive aspergillosis in patients with limited treatment options. Following an 80% workforce reduction in late October 2024, Matinas BioPharma Holdings, Inc. paused further clinical development of MAT2203 and its early-stage internal LNC pipeline (focused on oncology and inflammatory diseases) to conserve cash. The Company is actively seeking a licensing, sale, or other similar transaction for MAT2203 to advance its development into Phase 3, while maintaining its Investigational New Drug Application (IND) and intellectual property.

Market Position: Matinas BioPharma Holdings, Inc. operates within the global antifungal market, valued at approximately $15.8 billion in 2023 and projected to reach $20.5 billion by 2030. The global invasive fungal infection (IFI) market, a key target for MAT2203, was valued at over $7.2 billion in 2021 and is expected to reach $10.4 billion by 2030. There are an estimated 1.5 million cases of IFIs globally each year, with significant treatment costs (e.g., over $1.3 billion for aspergillosis-associated hospitalizations in the U.S.). The market faces challenges from limited systemic antifungal drug classes and increasing drug-resistant strains, creating an urgent need for new, less toxic agents. MAT2203 aims to address this need by offering an oral, safe, and well-tolerated formulation of amphotericin B, potentially preserving or increasing efficacy while eliminating nephrotoxicity and enabling outpatient administration. MAT2203 has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for multiple indications, and Orphan Drug Designation for cryptococcosis, potentially offering up to 12 years of marketing exclusivity in the United States upon approval.

Recent Strategic Developments:

• October 2024: Terminated non-binding term sheet for global rights to MAT2203. Implemented an 80% workforce reduction (15 positions, including 3 senior management) and ceased all product development activities to conserve cash.
• February 2024: Announced agreement with the United States Food and Drug Administration (FDA) on the design of a single Phase 3 registration trial (ORALTO trial) for MAT2203 in patients with invasive aspergillosis who have limited treatment options.
• March 2024: Stated that commencement of the ORALTO trial requires either a partnership transaction or significant additional capital.
• April 2, 2024: Entered into a securities purchase agreement with institutional investors for the sale of 666,667 shares of common stock and warrants to purchase up to 666,667 shares of common stock, generating approximately $10 million in gross proceeds.
• August 30, 2024: Effected a 1-for-50 reverse stock split of its common stock.
• February 13, 2025: Entered into a securities purchase agreement with investors for the sale of 3,300 shares of Series C Convertible Preferred Stock and warrants to purchase up to 11,262,808 shares of common stock, for aggregate gross proceeds of $3.3 million. An initial closing of $1.65 million occurred on February 13, 2025, with a second closing of $1.65 million on April 8, 2025, following shareholder approval. Funds are for general corporate purposes, focusing on reducing operating expenses and exploring strategic alternatives for MAT2203 and Matinas BioPharma Holdings, Inc.
• March 2025: Dr. Robin L. Smith, MD, MBA, was appointed to the Board of Directors.

Geographic Footprint: Matinas BioPharma Holdings, Inc. maintains administrative offices in Bedminster, New Jersey (approximately 8,900 square feet, lease expires June 2029) and laboratory space in Bridgewater, New Jersey (approximately 14,000 square feet, lease expires September 2027). The planned ORALTO trial for MAT2203, if commenced, is intended to be conducted at approximately 65 investigator sites across the U.S., Europe, South America, the Middle East, and Asia Pacific. The Company's Compassionate/Expanded Use Access Program for MAT2203 has enrolled patients at multiple healthcare institutions within the United States.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A
• Operating Margin: N/A
• Net Margin: N/A

Investment in Growth:

• R&D Expenditure: $11,433 thousand (2024)
• Capital Expenditures: $0 thousand (2024)

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $0 thousand
• Dividend Payments: $0 thousand
• Dividend Yield: N/A
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $7,284 thousand (as of December 31, 2024)
• Total Debt: Matinas BioPharma Holdings, Inc. has no traditional debt. Total liabilities were $5,051 thousand as of December 31, 2024, primarily consisting of lease liabilities and accrued expenses.
• Net Cash Position: $7,284 thousand (Cash and Equivalents)
• Debt Maturity Profile:
  • Operating Lease Liabilities (undiscounted): $998 thousand (2025), $1,040 thousand (2026), $944 thousand (2027), $273 thousand (2028), $138 thousand (2029), $138 thousand (thereafter).
  • Finance Lease Liabilities (undiscounted): $7 thousand (2025), $7 thousand (2026), $7 thousand (2027).

Cash Flow Generation:

• Operating Cash Flow: $(15,885) thousand (2024)
• Free Cash Flow: $(15,885) thousand (2024)

Operational Excellence

Production & Service Model: Matinas BioPharma Holdings, Inc. has limited in-house manufacturing capabilities for its LNC Platform product candidate, MAT2203, sufficient for clinical supplies. The Company is exploring relationships with third-party contract manufacturers for the formulation and manufacture of MAT2203 for future clinical development and potential commercialization, which would necessitate technology transfer.

Supply Chain Architecture: Key Suppliers & Partners:

• Active Pharmaceutical Ingredient (API) Suppliers: Several potential third-party suppliers for amphotericin B (MAT2203 API). Formal supply agreements are not yet in place, but the Company believes it can secure supply.
• Contract Manufacturing Organizations (CMOs): Patheon, a wholly owned subsidiary of ThermoFisher, is engaged for commercial manufacture preparation of MAT2203.
• Research Collaborators: National Institutes of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) has provided assistance and financial support for MAT2203 development.
• Licensor: Rutgers University, The State University of New Jersey, for certain patents related to the LNC Platform.

Facility Network:

• Administrative: Approximately 8,900 square feet of office space in Bedminster, New Jersey.
• Research & Development/Manufacturing: Approximately 14,000 square feet of laboratory and manufacturing space in Bridgewater, New Jersey, used for in-house clinical supply production.
• Distribution: Not explicitly detailed, but future commercialization would rely on partners.

Market Access & Customer Relationships

Go-to-Market Strategy: Matinas BioPharma Holdings, Inc. currently lacks a sales and marketing infrastructure and does not plan to develop one. Its strategy for commercializing MAT2203, if approved, is to secure one or more development and/or commercialization partners, likely well-funded and experienced third-party biotech or pharmaceutical companies.

Customer Portfolio: Enterprise Customers: The Company's primary "customers" for MAT2203 commercialization are prospective development and/or commercialization partners. Strategic Partnerships:

• National Institutes of Health (NIH): Provided assistance and financial support for MAT2203 development.
• BioNTech SE: Engaged in a research collaboration to evaluate mRNA formats utilizing the LNC Platform (agreement expired April 2023).
• Genentech Inc.: Completed a feasibility study agreement for oral formulations using the LNC Platform (obligations completed 2023).
• Compassionate/Expanded Use Access Program: 37 patients have been enrolled at multiple U.S. healthcare institutions, including the University of Michigan, Johns Hopkins, Nationwide Children’s Hospital, City of Hope, Vanderbilt University Medical Center, the National Institutes of Health, Children’s Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, and the University of California, San Diego School of Medicine. The majority of enrolled patients are post-transplant or undergoing treatment for underlying malignancies. 7 patients treated for invasive aspergillosis showed positive results. All patients experiencing renal toxicity from AmBisome saw renal function return to baseline after transitioning to MAT2203.

Geographic Revenue Distribution: Not applicable as Matinas BioPharma Holdings, Inc. does not currently generate product revenue. Future revenue, if any, would depend on commercialization in the U.S. and potentially foreign markets through collaborations.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are characterized by rapid technological advancements, intense competition, and a strong focus on proprietary products. The global antifungal market is substantial and growing, driven by the increasing incidence of invasive fungal infections (IFIs) and the rise of drug-resistant strains. There is a critical unmet need for new antifungal agents with improved safety profiles and efficacy against resistant pathogens, as highlighted by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: MAT2203, if approved, would primarily compete with existing antifungal classes including polyenes, azoles, and echinocandins.

• Approved Branded Therapies: Cancidas (caspofungin, marketed by Merck & Co.), Eraxis (anidulafungin, marketed by Pfizer, Inc.), Mycamine (micafungin, marketed by Astellas Pharma US, Inc.), Diflucan (fluconazole, marketed by Pfizer, Inc.), Noxafil (posaconazole, marketed by Merck & Co.), Vfend (voriconazole, marketed by Pfizer, Inc.), Sporanox (itraconazole, marketed by Jansen Pharmaceuticals, Inc.), Ambisome (liposomal amphotericin B, marketed by Astellas Pharma US, Inc.), Abelcet (lipid complex amphotericin B, marketed by Sigma Tau Pharmaceuticals Inc.), Rezzayo (rezafungin, marketed by Melinta Therapeutics), Brexafemme (Ibrexafungerp marketed by GlaxoSmithKline), and amphotericin B deoxycholate (marketed by X-Gen Pharmaceuticals, Inc.).
• Generic Competition: Generic versions of many approved products are available or expected, potentially increasing price competition.

Emerging Competitive Threats:

• Product Candidates in Clinical Development: Olorofim (F2G, Ltd), fosmanogepix (Basilea), and AM2-19 (Elion Therapeutics).

Competitive Response Strategy: Matinas BioPharma Holdings, Inc. aims to leverage the unique advantages of its LNC Platform and MAT2203's product profile (oral, reduced toxicity, potential for prolonged use) to differentiate itself. The Company's strategy includes pursuing regulatory designations for market exclusivity and seeking partnerships with larger pharmaceutical companies to access commercialization resources.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Product Development Uncertainty: Matinas BioPharma Holdings, Inc. is in early stages of development, with no guarantee of regulatory approval or successful commercialization for any product candidate. Clinical development of MAT2203 and internal LNC pipeline programs are currently paused.
• Partnership Dependency: The Company requires a partnership or significant additional capital to commence the ORALTO trial for MAT2203, with no assurance of successfully consummating such a transaction. Failure to secure a partner could lead to a winddown or dissolution of the Company.
• Competition: The biotechnology and pharmaceutical industries are highly competitive, with many competitors possessing greater financial and human resources, more advanced product candidates, and established market presence.
• Regulatory Delays/Failure: The process of obtaining regulatory approvals is lengthy, expensive, and uncertain. Any delays or rejections could significantly harm the business, increase costs, and delay market entry.
• Post-Approval Restrictions: Even with marketing approval, products may face significant restrictions on indicated uses, marketing, or require costly post-approval studies and Risk Evaluation and Mitigation Strategies (REMS).
• Healthcare Policy Changes: Legislative and regulatory changes in healthcare (e.g., Affordable Care Act, Inflation Reduction Act of 2022) could adversely impact drug pricing, reimbursement, and overall profitability.

Technology Disruption:

• Reliance on Licensed Technology: The Company heavily relies on its LNC Platform and certain patents exclusively licensed from Rutgers University. Loss of these rights or defects in the intellectual property could severely impair business operations.
• Intellectual Property Protection: Protecting intellectual property rights is difficult and costly. Patents may be challenged, invalidated, or circumvented, and trade secrets are vulnerable to independent discovery or unauthorized disclosure.
• IP Infringement Claims: The Company's product candidates may infringe on third-party intellectual property rights, potentially leading to costly litigation, development delays, or the inability to commercialize products.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Manufacturing Dependency: Matinas BioPharma Holdings, Inc. is entirely dependent on third-party contract manufacturers for the production of its product candidates. Failure of these third parties to obtain regulatory approval, provide sufficient quantities, or maintain acceptable quality/prices could halt or delay commercialization efforts.
• Raw Material Reliance: Reliance on third parties for raw materials introduces risks related to availability, cost control, delivery schedules, reliability, and quality.

Capacity Constraints:

• Limited in-house manufacturing capacity for clinical supplies necessitates reliance on third parties for commercial scale production, which may face challenges in scale-up and optimization.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Uncertainty: Matinas BioPharma Holdings, Inc. has incurred significant losses since inception and expects to continue incurring losses, raising substantial doubt about its ability to continue as a going concern without additional funding or a partnership.
• Funding Requirements: The Company requires substantial additional funding to support operations and future development, which may not be available on acceptable terms or at all, potentially forcing delays or termination of programs.
• Dilution Risk: Future equity financings could result in significant dilution to existing stockholders.
• Net Operating Loss (NOL) Limitations: The ability to utilize U.S. federal net operating loss carryforwards and tax credits may be limited by Section 382 of the Internal Revenue Code due to potential ownership changes.
• Royalty Obligations: The Company is obligated to pay significant annual royalties (up to $35 million) to former Series A Preferred Stockholders upon FDA or EMA approval and/or sales/licensing of MAT2203.

Regulatory & Compliance Risks:

• Ongoing Regulatory Compliance: Post-approval, products are subject to pervasive and continuing regulation by the FDA and other authorities, including requirements for manufacturing, labeling, advertising, and adverse event reporting, incurring significant ongoing expenses.
• Healthcare Fraud and Abuse Laws: Marketing activities are subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act), with potential for civil or criminal penalties for non-compliance or off-label promotion.
• Health Privacy Laws: Compliance with data protection laws such as HIPAA, HITECH, and GDPR is required, with potential for regulatory sanctions or litigation for breaches.
• Internal Control Weakness: A material weakness in internal control over financial reporting was identified as of December 31, 2024, related to the timely preparation and review of indefinite-lived assets impairment assessment, which could affect financial reporting reliability.

Innovation & Technology Leadership

Research & Development Focus: Matinas BioPharma Holdings, Inc.'s core R&D focus is its Lipid Nanocrystal (LNC) platform delivery technology, aimed at redefining intracellular delivery of nucleic acids and small molecules. The lead product candidate, MAT2203 (oral amphotericin B), is an antifungal drug developed using this platform. While the Company previously sought to develop an internal pipeline for oncology and inflammatory diseases using the LNC Platform, these early-stage programs are currently paused. R&D expenditures were $11,433 thousand in 2024, a decrease from $14,489 thousand in 2023, reflecting the pause in development activities.

Intellectual Property Portfolio: Matinas BioPharma Holdings, Inc. protects its technology through a combination of patents, trade secrets, proprietary know-how, and regulatory exclusivity.

• Exclusively Licensed IP (from Rutgers University): As of March 31, 2025, this portfolio includes 1 pending U.S. non-provisional patent application, 6 U.S. patents, and 49 granted foreign patents, providing protection until at least 2033 (excluding adjustments/extensions). These cover the proprietary chemistry technology for LNC and geodate cochleates, and the formulation of active pharmaceutical ingredients like MAT2203.
• Matinas-Owned IP: As of March 31, 2025, the Company's owned portfolio includes:
  • LNC Platform and users: 5 pending U.S. provisional applications, 2 pending U.S. non-provisional applications, 2 pending PCT applications, 13 pending foreign applications, and 20 granted foreign patents (Europe, China, Brazil, Canada, Japan, Korea, Australia, Mexico).
  • Compositions and methods for enhancing tissue penetration of an active agent in an LNC: 1 issued U.S. patent, 7 issued foreign patents, and 1 pending foreign patent application, expected to expire in 2036.
  • LNC compositions and methods for treating mycobacteria infection: 9 foreign patents, expected to expire in 2036.
  • LNC compositions and methods for treating cryptococcus infections: 1 U.S. issued patent, 1 pending non-provisional U.S. patent application, 2 issued foreign patents, and 4 pending applications, expected to expire in 2037.
  • Additional LNC compositions and methods for treating cryptococcus infections: 1 pending non-provisional U.S. patent application and 4 pending applications, expected to expire in 2040.
  • Methods for controlling LNC particle size: 1 PCT application, expected to expire in 2043.
  • LNC compositions and methods for treating mucormycosis: 1 PCT application, expected to expire in 2043.
• Trade Secrets & Know-how: Significant aspects of the LNC Platform are based on unpatented trade secrets and know-how, protected by confidentiality and invention assignment agreements with employees, consultants, and partners.
• Trademark Strategy: Plans to seek trademark protection in the United States and internationally.

Technology Partnerships: Matinas BioPharma Holdings, Inc. has engaged in strategic alliances and research collaborations, including with Rutgers University for its core LNC Platform, and with the National Institutes of Health (NIH) for financial support in MAT2203 development. Past collaborations include BioNTech SE and Genentech Inc. for LNC Platform evaluation and development, and the Cystic Fibrosis Foundation (CFF) for MAT2501 (development paused).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company implemented an 80% workforce reduction in October 2024, which included three members of senior management. The 2013 Equity Compensation Plan expired in May 2024, and the Company intends to seek shareholder approval for a new equity compensation plan at its next annual meeting.

Board Composition: As of March 2025, the Board of Directors includes Jerome D. Jabbour, Evelyn D’An, Keith Murphy, Edward Neugeboren, and Robin L. Smith, MD, MBA. Evelyn D’An, Keith Murphy, Edward Neugeboren, and Robin L. Smith are designated as independent directors. The Board's expertise spans corporate governance, financial oversight, accounting, biotechnology, product development, general management, and the pharmaceutical and healthcare industries.

• Audit Committee: Evelyn D’An (Chair), Robin L. Smith, Edward Neugeboren. Ms. D’An is an audit committee financial expert. The committee met four times in 2024.
• Compensation Committee: Edward Neugeboren (Chair), Keith Murphy. The committee met four times in 2024.
• Nominating and Corporate Governance Committee: Keith Murphy (Chair), Evelyn D’An, Robin L. Smith. The committee met four times in 2024.

Human Capital Strategy

Workforce Composition: As of March 31, 2025, Matinas BioPharma Holdings, Inc. had three full-time employees and retained the services of approximately four independent contractors/consultants. This represents an 80% reduction in workforce implemented in late October 2024, which eliminated 15 positions, including three members of senior management.

Talent Management: Acquisition & Retention: The Company's ability to compete in the pharmaceutical industry depends on attracting and retaining highly qualified managerial, scientific, and medical personnel. While the 2013 Equity Compensation Plan expired in May 2024, the Company intends to seek shareholder approval for a new equity compensation plan to provide incentives for talent acquisition and retention.

Regulatory Environment & Compliance

Regulatory Framework: Matinas BioPharma Holdings, Inc. operates under a comprehensive regulatory framework governing drug development and commercialization in the United States and internationally. This includes adherence to the Federal Food, Drug, and Cosmetic Act (FDCA), Good Laboratory Practice (cGLP) regulations for nonclinical studies, Investigational New Drug Application (IND) requirements for human clinical trials, Good Clinical Practices (GCP) for clinical trials, and New Drug Application (NDA) processes for marketing approval. Manufacturing facilities must comply with current Good Manufacturing Practices (cGMP). The Company's product candidates may also be subject to Risk Evaluation and Mitigation Strategies (REMS) and post-approval surveillance. Regulatory designations such as Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug Designation provide specific incentives and exclusivity periods. International market access requires compliance with varying regulatory requirements, including those in the European Union (e.g., European Clinical Trials Directive, Marketing Authorization Application).

Legal Proceedings: Matinas BioPharma Holdings, Inc. is not currently a party to any legal proceedings and is not aware of any claims or actions pending or threatened against it.

Tax Strategy & Considerations

Tax Profile: Matinas BioPharma Holdings, Inc.'s effective tax rate was 0.33% for 2024 and 0.00% for 2023. The difference between the statutory U.S. federal rate and the effective tax rate is primarily due to a valuation allowance offsetting deferred tax assets. As of December 31, 2024, the Company had Federal net operating loss carryforwards of $38,080 thousand (expiring starting 2032) and $88,364 thousand (indefinite carryforward period), along with federal and state research and development tax credit carryforwards of $4,469 thousand. The Tax Cuts and Jobs Act of 2017 imposes limitations on net operating loss deductions (80% of net taxable income for losses after December 31, 2017) and requires capitalization and amortization of R&D costs for U.S. tax purposes effective January 1, 2022, which increases deferred tax assets.

Insurance & Risk Transfer

Risk Management Framework: Matinas BioPharma Holdings, Inc. maintains product liability insurance coverage for its clinical trials in the amount of greater than or equal to $5 million in the aggregate.